CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics to Participate in Upcoming Investor Conferences

06 9 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 9 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Reports Second Quarter 2022 Financial Results

04 8 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

04 8 2022 07:30:01 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 8 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 4, 2022

21 7 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

05 7 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

01 7 2022 03:35:20 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Convertible Senior Notes Offering

29 6 2022 16:35:18 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

24 6 2022 07:30:00 提供 Nasdaq GlobeNewswire